keyword
MENU ▼
Read by QxMD icon Read
search

Dupilumab

keyword
https://www.readbyqxmd.com/read/29193016/dupilumab-with-concomitant-topical-corticosteroids-in-adult-patients-with-atopic-dermatitis-who-are-not-adequately-controlled-with-or-are-intolerant-to-ciclosporin-a-or-when-this-treatment-is-medically-inadvisable-a-placebo-controlled-randomized-phase-3-clinical
#1
M de Bruin-Weller, D Thaçi, C H Smith, K Reich, M Cork, A Radin, Q Zhang, B Akinlade, A Gadkari, L Eckert, T Hultsch, Z Chen, G Pirozzi, N M H Graham, B Shumel
BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disease that may require systemic therapy. Ciclosporin A (CsA) is a widely-used, potent immunosuppressant for AD. CsA is not effective in all patients, and side effects limit its use. Dupilumab, a fully human anti-interleukin (IL)-4 receptor-alpha monoclonal antibody, inhibits signaling of IL-4 and IL-13, key drivers of type 2/Th2-mediated inflammation, and is approved in the U.S.A. and the E.U. for the treatment of adults with moderate-to-severe AD...
November 28, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/29191053/diagnosis-and-management-of-conjunctivitis-for-the-dermatologist
#2
Melinda Gooderham, Julian McDonald, Kim Papp
Atopic dermatitis is a chronic, sometimes relapsing inflammatory skin condition that presents with pruritus and characteristic skin manifestations. Conjunctivitis is a common ocular comorbidity affecting almost half of patients with the risk increasing with atopic dermatitis severity. Recent targeted biologic therapies that successfully treat atopic skin disease, including dupilumab, which blocks interleukin (IL)-4 and IL-13, as well as agents that block IL-13 alone, have been associated with an increased rate of conjunctivitis in clinical trials...
November 1, 2017: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/29182975/adverse-events-of-dupilumab-in-adults-with-moderate-to-severe-atopic-dermatitis-a-meta-analysis
#3
Zuzhen Ou, Chao Chen, Aijun Chen, Yao Yang, Weikang Zhou
BACKGROUND: Dupilumab, a fully human monoclonal antibody against interleukin-4 receptor alpha, inhibits the signals of interleukin-4 and interleukin-13, and has also shown significant efficacy in patients with moderate-to-severe atopic dermatitis (AD), while the effect of it on adverse events remains controversial. OBJECTIVE: To assess the influence of dupilumab on adverse events in adults with moderate-to-severe AD. METHOD: Randomised controlled trials (RCTs) that compared dupilumab with a placebo for patients with moderate-to-severe AD were searched in the MEDLINE, EMBASE, Web of Science and Cochrane databases...
November 25, 2017: International Immunopharmacology
https://www.readbyqxmd.com/read/29176433/drug-updates-and-approvals-2017-in-review
#4
Geoffrey Mospan, Cortney Mospan, Shayna Vance, Alyssa Bradshaw, Kalyn Meosky, Kirklin Bowles
In 2017, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: brodalumab (Siliq), dapagliflozin and saxagliptin (Qtern), dupilumab (Dupixent), oxymetazoline (Rhofade), safinamide (Xadago), and sarilumab (Kevzara).
December 15, 2017: Nurse Practitioner
https://www.readbyqxmd.com/read/29122151/biologic-therapy-for-atopic-dermatitis-moving-beyond-the-practice-parameter-and-guidelines
#5
Mark Boguniewicz
Atopic dermatitis (AD), a common chronic pruritic inflammatory skin disease, impacts the quality of life of patients and caregivers and has become a global health problem. It is increasingly recognized as a disease not only of children but also of adults who may have a persistent or relapsing course from childhood or who develop new-onset adult disease. Besides well-established atopic comorbidities, associations with a number of nonatopic comorbidities have been reported. AD is characterized by both immune dysregulation and epidermal barrier dysfunction...
November 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29108767/biologics-in-the-treatment-of-severe-asthma
#6
REVIEW
S Quirce, E Phillips-Angles, J Domínguez-Ortega, P Barranco
Severe asthma is defined as asthma which requires treatment with high dose inhaled corticosteroids and with a second controller drug to prevent it from becoming uncontrolled or which remains uncontrolled despite this therapy. Patients with uncontrolled severe asthma require additional treatment options as add-on therapy, including biologics. Biologic therapies in asthma are designed to block key immune regulators, such as IgE, or certain pro-inflammatory cytokines, e.g. interleukin (IL)-5, IL-4, IL-13 or IL-17...
December 2017: Allergologia et Immunopathologia
https://www.readbyqxmd.com/read/29098604/are-biologics-efficacious-in-atopic-dermatitis-a-systematic-review-and-meta-analysis
#7
REVIEW
Igor Snast, Ofer Reiter, Emmilia Hodak, Rivka Friedland, Daniel Mimouni, Yael Anne Leshem
BACKGROUND: Current systemic treatments for atopic dermatitis (AD) offer limited efficacy and are often restricted by safety concerns. Biologics may address the unmet need for improved AD therapeutics. OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of biologic agents in AD. METHODS: A systematic review and meta-analysis of studies evaluating AD patients treated with biologics was performed. The primary outcome was the Eczema Area and Severity Index (EASI)-75 response, while secondary outcomes were SCOring Atopic Dermatitis (SCORAD)-75, EASI-50, SCORAD-50, Investigator Global Assessment 0/1 responses, change in responses from baseline, and adverse events...
November 2, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/29091379/dupilumab-for-moderate-to-severe-atopic-dermatitis
#8
R Vangipuram, S K Tyring
Atopic dermatitis (AD) is the most common chronic inflammatory disease affecting 2-10% of adults and up to 15-30% of children. Despite a rising prevalence, effective and safe therapeutics for patients with moderate-to-severe AD are limited due to toxicity and side effects. Dupilumab, an interleukin (IL)-4 and IL-13 antagonist that limits type 2 T helper (Th2) driven inflammatory activity, is a promising therapeutic option. In clinical trials, it has demonstrated efficacy by reducing clinical activity and symptoms, and showed improvement in the AD genomic phenotype, including a significant reduction in Th2 chemokines and reversal of key epidermal markers of AD...
November 2017: Skin Therapy Letter
https://www.readbyqxmd.com/read/29063435/prescription-treatment-options
#9
Brad Ackerson, Ryan Thorpe, Matilda W Nicholas
Atopic dermatitis frequently requires the use of over-the-counter and prescription medications for effective management. Emollients and topical corticosteroids are effective for most patients and are the most commonly utilized agents by experienced dermatologists. Antihistamines, antibiotics, and calcineurin inhibitors may also prove helpful in the correct clinical scenarios. Severe atopic dermatitis, however, can be difficult to manage and not infrequently require substantial immunomodulatory medications. Targeted molecular therapies, such as dupilumab, are promising, emerging atopic dermatitis therapies...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29059087/controversies-and-opportunities-in-severe-asthma
#10
Marc Humbert, William Busse, Nicola A Hanania
PURPOSE OF REVIEW: Despite currently available treatments, many asthma patients remain inadequately controlled, but identifying distinct patient populations (phenotypes/endotypes) may optimize their management. This review discusses some of the controversies and opportunities for improved disease control in severe asthma. RECENT FINDINGS: Currently approved anti-immunoglobulin E and anti-interleukin 5 biologics, which target specific pathways instead of using a 'one size fits all' strategy, are efficacious and well tolerated therapies for severe asthma...
January 2018: Current Opinion in Pulmonary Medicine
https://www.readbyqxmd.com/read/29036019/targeting-the-interleukin-4-and-interleukin-13-pathways-in-severe-asthma-current-knowledge-and-future-needs
#11
Amit D Parulekar, Christina C Kao, Zuzana Diamant, Nicola A Hanania
PURPOSE OF REVIEW: Severe asthma is a heterogeneous disease that can be classified into phenotypes and endotypes based upon clinical or biological characteristics. Interleukin (IL)-4 and IL-13 play a key role in type 2 (T2) asthma. This article reviews the signaling pathway of IL-4 and IL-13 and highlights its targeted therapy in severe asthma. RECENT FINDINGS: Several clinical trials of biologics targeting the IL-4/IL-13 pathway have recently been completed. In patients with severe, uncontrolled asthma, targeting IL-13 alone with biologics including lebrikizumab and tralokinumab has not shown consistent reduction in asthma exacerbations...
October 13, 2017: Current Opinion in Pulmonary Medicine
https://www.readbyqxmd.com/read/29017221/-biologicals-in-the-treatment-of-bronchial-asthma
#12
I Haasler, C Taube
Biologicals are a therapeutic option for patients with severe asthma. Difficult asthma in patients with untreated comorbidities or persistent trigger factors is much more common than severe refractory asthma. Optimized medical treatment, adherence to medication, elimination of trigger factors and treatment of comorbidities are essential before escalating the therapy with a biological. A careful phenotyping of patient with severe asthma is necessary because all available biological are only effective in certain phenotypes of the disease...
October 2017: Pneumologie
https://www.readbyqxmd.com/read/28990423/dupilumab-for-the-treatment-of-asthma
#13
Corrado Pelaia, Alessandro Vatrella, Luca Gallelli, Rosa Terracciano, Paolo Navalesi, Rosario Maselli, Girolamo Pelaia
Dupilumab is a fully human IgG4 monoclonal antibody directed against the α subunit of the interleukin (IL)-4 receptor (IL-4Rα). Since the activation of IL-4Rα is utilized by both IL-4 and IL-13 to mediate their pathophysiological effects, dupilumab behaves as a dual antagonist of these two sister cytokines, which blocks IL-4/IL-13-dependent signal transduction. Areas covered: Herein, the authors review the cellular and molecular pathways activated by IL-4 and IL-13, which are relevant to asthma pathobiology...
October 8, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28987493/risk-of-infection-in-patients-with-atopic-dermatitis-treated-with-dupilumab-a-meta-analysis-of-randomized-controlled-trials
#14
Patrick Fleming, Aaron M Drucker
BACKGROUND: Atopic dermatitis (AD) is characterized by skin barrier defects, Th2 activation, and increased risk for cutaneous and extracutaneous infections. In clinical trials, dupilumab appeared to decrease rates of skin infections in AD. OBJECTIVE: We aimed to determine the impact of dupilumab on rates of skin and other infections in patients with moderate-to-severe AD. METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) of dupilumab for AD...
October 4, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28979129/dupilumab-in-the-management-of-moderate-to-severe-asthma-the-data-so-far
#15
REVIEW
Pilar Barranco, Elsa Phillips-Angles, Javier Dominguez-Ortega, Santiago Quirce
Severe asthma constitutes illness in a relatively small proportion of all patients with asthma, but it is a major public health problem - with considerable effect on morbidity, mortality, as well as a high burden on health care resources. Regardless of effective treatments being widely available and the existence of treatment guidelines, a large population of severe asthma cases remain uncontrolled. Achieving and maintaining asthma control in this group of patients is, therefore, of utmost importance. The recognition of distinct inflammatory phenotypes within this population has driven the development of targeted biological therapies - particularly, selective targeted monoclonal antibodies (mAbs)...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28971769/new-therapeutic-targets-and-drugs-for-the-treatment-of-asthma
#16
Mateus Feitosa Alves, Diogo Vilar da Fonsec, Sílvia Adelaide Linhares de Melo, Marcus Tullius Scotti, Luciana Scotti, Sócrates Golzio Dos Santos, Margareth de Fátima Formiga Melo Diniz
Asthma is an inflammatory disease which affects millions of people worldwide. Therefore, it is necessary search for new sources of therapies for the treatment of these patients in order to improve their quality of life. From content analysis of new therapeutic targets literature, there are various targets and drugs reported as promising for treatment asthma. Interleukins involved in inflammatory processes are often presented as candidate targets for new drugs. The action of such therapeutics would not only affect interleukins, but also in their receptors...
September 27, 2017: Mini Reviews in Medicinal Chemistry
https://www.readbyqxmd.com/read/28970084/expert-perspectives-on-management-of-moderate-to-severe-atopic-dermatitis-a-multidisciplinary-consensus-addressing-current-and-emerging-therapies
#17
REVIEW
Mark Boguniewicz, Andrew F Alexis, Lisa A Beck, Julie Block, Lawrence F Eichenfield, Luz Fonacier, Emma Guttman-Yassky, Amy S Paller, David Pariser, Jonathan I Silverberg, Mark Lebwohl
Atopic dermatitis (AD) is a common, chronic, relapsing, inflammatory skin disease that affects children and adults. Until recently, the only Food and Drug Administration-approved systemic treatment option for patients with moderate-to-severe AD was systemic steroids, which are not recommended by current guidelines and are commonly associated with disease rebound. Instead, clinicians choose from several off-label immunosuppressants, which can have serious adverse effects. A significant number of these patients go untreated...
November 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28948572/overlapping-effects-of-new-monoclonal-antibodies-for-severe-asthma
#18
REVIEW
Christian Domingo
Among the monoclonal antibodies (mAbs) developed for severe asthma treatment, three have already been marketed. Omalizumab was the first, more than 10 years ago; today, mepolizumab and reslizumab are also available in the European Union and the US. Omalizumab blocks free immunoglobulin E (IgE), mepolizumab and reslizumab block an interleukin (IL-5). In the near future, dupilumab and benralizumab are expected to emerge as two new alternatives. Benralizumab blocks the receptor for IL-5 (IL5-Rα) and has a direct cytotoxic effect on eosinophils, and dupilumab blocks the α-unit of the heterodimeric receptor for IL-4 and IL-13 (IL-4Rα); as a result, dupilumab can block both IL-4 and IL-13...
October 2017: Drugs
https://www.readbyqxmd.com/read/28933010/economic-evaluation-of-dupilumab-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-in-adults
#19
Andreas Kuznik, Gaëlle Bégo-Le-Bagousse, Laurent Eckert, Abhijit Gadkari, Eric Simpson, Christopher N Graham, LaStella Miles, Vera Mastey, Puneet Mahajan, Sean D Sullivan
INTRODUCTION: Dupilumab significantly improves signs and symptoms of atopic dermatitis (AD), including pruritus, symptoms of anxiety and depression, and health-related quality of life versus placebo in adults with moderate-to-severe AD. Since the cost-effectiveness of dupilumab has not been evaluated, the objective of this analysis was to estimate a value-based price range in which dupilumab would be considered cost-effective compared with supportive care (SC) for treatment of moderate-to-severe AD in an adult population...
December 2017: Dermatology and Therapy
https://www.readbyqxmd.com/read/28919788/innovative-treatments-for-severe-refractory-asthma-how-to-choose-the-right-option-for-the-right-patient
#20
REVIEW
Francesco Menzella, Carla Galeone, Francesca Bertolini, Claudia Castagnetti, Nicola Facciolongo
The increasing understanding of the molecular biology and the etiopathogenetic mechanisms of asthma helps in identification of numerous phenotypes and endotypes, particularly for severe refractory asthma. For a decade, the only available biologic therapy that met the unmet needs of a specific group of patients with severe uncontrolled allergic asthma has been omalizumab. Recently, new biologic therapies with different mechanisms of action and targets have been approved for marketing, such as mepolizumab. Other promising drugs will be available in the coming years, such as reslizumab, benralizumab, dupilumab and lebrikizumab...
2017: Journal of Asthma and Allergy
keyword
keyword
25750
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"